A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia
Hematology Reports · 18.04.2024 · 16 (2) · 244-254
DOI: 10.3390/hematolrep16020024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 18.04.2024. Verfasst von Anna Candoni und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via del Pozzo 71, 41123 Modena, Italy. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Menin inhibitors are new and promising agents currently in clinical development that target the HOX/MEIS1 transcriptional program which is critical for leukemogenesis in histone-lysine N-methyltransferase 2A-rearranged (KMT2Ar) and in NPM1-mutated (NPM1mut) acute leukemias. The mechanism of action of this new class of agents is based on the disruption of the menin–KMT2A complex (consisting of chromatin remodeling proteins), leading to the differentiation and apoptosis of AML cells expressing KMT2A or with mutated NPM1. To date, this new class of drugs has been tested in phase I and II clinical trials, both alone and in combination with synergistic drugs showing promising results in terms of response rates and safety in heavily pre-treated acute leukemia patients. In this brief review, we summarize the key findings on menin inhibitors, focusing on the mechanism of action and preliminary clinical data on the treatment of acute myeloid leukemia with this promising new class of agents, particularly revumenib and ziftomenib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via del Pozzo 71, 41123 Modena, Italy.
ORCID-Profile: Anna Candoni
Zitieren
APA
Candoni, A., & Coppola, G. (2024). A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematology Reports, 16(2), 244-254. https://doi.org/10.3390/hematolrep16020024
Vancouver
Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematology Reports. 2024;16(2):244-254. doi:10.3390/hematolrep16020024
BibTeX
@article{Candoni2024,
author = {Candoni, Anna and Coppola, Gabriele},
title = {A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia},
journal = {Hematology Reports},
year = {2024},
volume = {16},
number = {2},
pages = {244--254},
doi = {10.3390/hematolrep16020024}
}
EUVIMED